Clinical trial NCT04884243: Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction
Official title: A Phase 2 Multicenter, Double-masked, Randomized, Vehicle-controlled, Parallel Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Meibomian Gland Dysfunction
Lead sponsor: Cloudbreak Therapeutics, LLC
Sponsor class: INDUSTRY
First posted: 2021-05-12
Enrollment: 92
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: STUDY DESIGN

Structure:

Multicenter, randomized, double-masked, vehicle-controlled, parallel group study.

Duration:

3 months of TID treatment.

Treatment Groups, Dosing, and Treatment Regimen:

Study Treatment: CBT-006 topical ophthalmic solution Control Treatment: CBT-006 vehicle

Detailed description: Structure:

Multicenter, randomized, double-masked, vehicle-controlled, parallel group study.

Duration:

3 months of TID treatment.

Treatment Groups, Dosing, and Treatment Regimen:

Study Treatment: CBT-006 topical ophthalmic solution Control Treatment: CBT-006 vehicle

Eligibility criteria: Inclusion Criteria:

* Diagnosed with MGD in both eyes and meet the following:

  1. Ocular discomfort Score (ODS) ≥ 2
  2. Visual Analog Scale (VAS) level is 35-90% for at least 1 of the 7 categories
  3. Total Cornea staining grade ≥ 3
  4. Total meibum quality score (MQS) is between 6-17 from the sum of the 6 lower eyelid central glands in at least one lower eyelid
  5. TBUT ≤ 5 s
  6. Schirmer I Test (anaesthetized) ≥ 5 mm/5 min in study eye
  7. BCVA LogMAR ≥ +0.7 in each eye
* All patients of both genders ≥ 18 years
* Willing to withhold the use of artificial tears and lubricants during the treatment phase;
* Able to provide written informed consent and comply with study assessments for the full duration of the study.

Exclusion Criteria:

* Uncontrolled systemic disease in the opinion of the Investigator
* Active allergies with symptoms that may confound the data, active ocular infection requiring treatment, or ocular surface inflammatory disease unrelated to MGD or DED, including chalazion, inflamed pinguecula, and viral illness
* History of ocular herpes disease in either eye
* Incisional ocular surgery within 6 months or ocular laser surgery within 3 months
* Use of topical treatment of the eye/eyelid with antibiotics, NSAIDS, or vasoconstrictors to treat MGD or DED within 14 days of screening; steroids, cyclosporin A or lifitegrast within 28 days of screening
* Current or anticipated use of other topical ophthalmic medications in the study eye. (Patients must have discontinued the use of ophthalmic medications in the study eye for at least 2 weeks prior to the screening visit, the use of diagnostic medications as part of the eye exam prior to screening and artificial tears is allowed.)
* Anticipated wearing of contact lenses during any portion of the study. (Patients, who wear soft contact lenses should discontinue wearing them at least 3 days prior to screening visit. Patients wearing rigid gas permeable or hard contact lenses should discontinue wearing them at least 3 weeks prior to screening visit.)
* Active rosacea involving the eyelids within 60 days of screening
* Current enrollment in an investigational drug or device study or participation in such a study within 30 days prior to entry into this study
* Any condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study
* Female patients who are pregnant, nursing, or planning a pregnancy during the study

Primary outcomes:
measure: IOP of Study Eye Related to Safety
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Newport Beach
country: United States
facility: Eye Research Foundation
state: California
Study officials:
affiliation: Cloudbreak Therapeutics, LLC
name: Rong Yang
role: STUDY_DIRECTOR
References: